Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Investor Presentation (June 2026)
42 slides from Inovio Pharmaceuticals's investor presentation, June 2026
Slide 1: Corporate Presentation
Corporate Presentation June 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: Company Overview
Company Overview • Focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases • Targeting diseases with high unmet need and market opportunity • Biologics License Application (BLA) for lead program (INO-3107) accepte
Slide 4: Advancing a Diversified Clinical Pipeline
Advancing a Diversified Clinical Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5412 Various targets HIV + c
Slide 5: DNA Medicine Platform
DNA Medicine Platform Harnessing the power of in vivo protein production
Slide 6: DNA Medicines: Customized In Vivo-Generated Proteins
DNA Medicines: Customized In Vivo-Generated Proteins TARGET BIOENGINEERING & PRECISELY PROPRIETARY MECHANISM OF ACTION SELECTION GENE SEQUENCING DESIGNED DEVICES PLASMIDS Skeletal Muscle Cell Selected gene Antigen-specific cytotoxic T cells to treat disease Binding/neutralizing antibodies and T cell
Slide 7: Key Features of our DNA Medicines Platform
Key Features of our DNA Medicines Platform Strengths include versatility & immunogenicity Well tolerated in nearly Targeted in vivo protein 19,000 administrations production to fight disease (~6k clinical trial participants) Ability to be re-dosed Ability to drive antibody and sustain immune respons
Slide 8: CELLECTRA Delivery Device Enhances Uptake of DNA Medicine
CELLECTRA® Delivery Device Enhances Uptake of DNA Medicine CELLECTRA 5PSP Track record of success in the clinic: • Intramuscular (IM) injection • Delivers DNA plasmid • Nearly 6,000 subjects & 19,000 contained in cartridge doses given by both investigational/ • Utilized in INOVIO’s commercial-ready
Slide 9: Focus on HPV-Related Diseases
Focus on HPV-Related Diseases
Slide 10: Human Papillomavirus: A Global Concern
Human Papillomavirus: A Global Concern • HPV is a group of viruses with approximately 200 types • Nearly everyone will become infected with some HPV type in their lifetime - The good news: ~90% of all infections clear naturally and don't result in disease - The bad news: persistent infection can lea
Slide 11: INOVIO's Development Experience Across HPV Spectrum
INOVIO’s Development Experience Across HPV Spectrum • Studies ranging from Phase 1 to Phase 3 • Involving patients with RRP, HSIL (cervical, anal & vulvar), head and neck cancers 12 trials, 900+ participants, 2000+ administrations in HPV-related diseases 11
Slide 12: Lead Candidate: INO-3107
Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) • BLA accepted by FDA for review under Accelerated Approval program • PDUFA target date of Oct. 30, 2026
Slide 13: Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) RRP: rare disease characterized by small, wart-like growths (papillomas) in the respiratory tract • Insufficient immune response that fails to prevent and clear HPV-6 and -11 infection leads to RRP Affects ~14,000 people in U.S.
Slide 14: Why every surgery matters to RRP patients
Why every surgery matters to RRP patients: “ The cumulative risk for injury increases with every surgery, but ultimately it only takes 1 surgical misadventure to permanently damage the larynx.” Factors Associated with Iatrogenic Laryngeal Injury in RRP Otolaryngology, 2024 Apr;170(4):1091-1098. doi:
Slide 15: Phase 1/2 Multi-Center Clinical Trial at 8 Clinical Sites
INO-3107 Phase 1/2 Multi-Center Clinical Trial at 8 Clinical Sites RRP-001 PHASE 1/2 OPEN-LABEL STUDY RRP-002 DURABILITY EXTENSION / FOLLOW-UP Baseline: DAY 0 52 WEEKS 104 WEEKS 156 WEEKS Patients Enrolled 4 Doses of INO-3107 Completed Study Consented to Follow Up Median Completed Follow Up Follow U
Slide 16: Statistically Significant Reduction in Surgeries
INO-3107 RRP-001 PHASE 1/2 TRIAL RESULTS Statistically Significant Reduction in Surgeries* Vast Majority of Patients Saw a Reduction in Surgery PARAMETERS CR Complete Response: no surgeries during a 52-week treatment phase PR Partial Response: a ≥ 50% reduction and less than 100% in surgeries compar
Slide 17: Reduction in Surgeries Continued to Improve After Year 1
INO-3107 Reduction in Surgeries Continued to Improve After Year 1 ORR was 72% at Week 52, improving to 86% by Week 104 for second twelve-month period The pre-treatment mean for surgeries in the year prior to start of INO-3107 was 4.1 (range 2-8) vs. 1.7 in Year 1 and 0.9 in Year 2 INO-3107 CLINICAL
Slide 18: Over 75% Fewer Surgeries 2 Years After Initial Treatment Regimen
INO-3107 Over 75% Fewer Surgeries 2 Years After Initial Treatment Regimen* MEAN SURGERIES PER YEAR PRE-TREATMENT WeekYEAR -52 to-10(N=32) (N=32) 4.1 WeekYEAR 1 (N=32) 52 Visit (N=32) 1.7 Longer-term therapy could offer POST-TREATMENT YEAR104 Week 2 (N=28) (N=28) 0.9 potential for maintenance and ext
Slide 19: Immunology Data Correlates with Clinical Response
INO-3107 Immunology Data Correlates with Clinical Response PRIOR TO INO-3107 Right kind of immune responses generated to fight HPV in all 32 patients (antigen specific cytotoxic T cell response) T cells observed to infiltrate the papilloma/airway tissue ONE YEAR FOLLOWING INO-3107 Created an anti-vi
Slide 20: Proposed Mechanism of Action
INO-3107 Proposed CIRCULATION Mechanism Expansion of pre-existing T Pre-existing of Action T cells in blood cells and Induction of novel Treatment with T cells in blood • Induce HPV INO-3107 antigen-specific Low T cell Immunotherapy Mass trafficking by T cell responses trafficking INO-3107 induced T
Slide 21: Surgery Should Be a Last Resort, Not a First-line Treatment
INO-3107 Surgery Should Be a Last Resort, Not a First-line Treatment INO-3107: RRP-001 PHASE 1/2 Open-label study at 8 sites (Patients with 2+ surgeries in year prior to treatment) Baseline: DAY 0 WEEK 52 • Initial Surgery: up to 14 days before first dose Patients Enrolled 4 Doses of INO-3107 Comple
Slide 22: Accelerated Approval: We Believe INO-3107 Meets FDA Criteria
INO-3107 Accelerated Approval: We Believe INO-3107 Meets FDA Criteria1 Meaningful therapeutic benefit Potential to meet remaining over existing treatments critical unmet need EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction in surgeries: • No required minimal residual • Ability to treat pat
Slide 23: The need for therapeutic alternatives to surgery remains immense
“ The need for therapeutic alternatives to surgery in our RRP community remains immense. Every surgery matters, every patient matters, and every patient deserves a treatment that works for them.” Kim McClellan President, RRP Foundation 23
Slide 24: Market Research Continues to Support Preferred Product Profile
INO-3107 Market Research Continues to Support Preferred Product Profile EFFICACY TOLERABILITY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Office-based administration that 100% reduction in surger
Slide 25: Advancing Commercial Readiness Plans
INO-3107 Advancing Commercial Readiness Plans Product Strategy: • Completed market research to understand unmet medical needs and customer perspective • Completed targeting, segmentation and product positioning work – supporting positive differentiation • Developed pricing strategy with price optimi
Slide 26: Late-Stage Pipeline Candidates
Late-Stage Pipeline Candidates • Designed to address high unmet needs, multiple near- and mid-term catalysts
Slide 27: Opportunity to Impact HPV-Related Oropharyngeal Squamous Cell Carcinoma
INO-3112 +LOQTORZI Opportunity to Impact HPV-Related Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma (Throat Cancer) • Throat cancer: high unmet need in fast-growing indication - Surpassed cervical cancer as most common HPV-related cancer diagnosed in the U.S. (~ 20,000 new cases/yr) -
Slide 28: Innovative Partnership for Combination Therapy for Glioblastoma (GBM)
INO-5412 Innovative Partnership to Advance Novel Combination Therapy for Glioblastoma (GBM) • GBM: most common and aggressive form of brain cancer - ~ 15,000 people diagnosed with GBM each year - Poor prognosis: typical life expectancy of 15-18 months, 5-year survival rate <10% • INO-5412 + cadonili
Slide 29: Support for GBM Research: Completed Phase 1/2 Combination Trial
INO-5401 (+ INO-9012) Support for GBM Research: Completed Phase 1/2 Combination Trial with PD-1 Checkpoint Inhibitor LIBTAYO® INO-5401 + INO-9012 in combination with a PD-1 checkpoint inhibitor elicited robust immune responses that potentially correlated with enhanced survival • LIBTAYO®: high-affin
Slide 30: Leveraging Key Advantages of DNA Medicine to Extend Ebola Protection
INO-4201 Leveraging Key Advantages of DNA Medicine to Extend Ebola Protection • Existing Ebola vaccines provide protection, but duration unclear - Two vaccines available (ERVEBO® and Zabdeno®)with limited or no boost options - With periodic outbreaks, multiple boosters might be needed during lifetim
Slide 31: Positive Topline Results from ApolloBio's Phase 3 Trial of VGX-3100
VGX-3100 Positive Topline Results from ApolloBio’s Phase 3 Trial of VGX-3100 in Cervical Dysplasia Patients • VGX-3100: INOVIO’s investigational DNA immunotherapy licensed to ApolloBio - Currently in development by ApolloBio in China as potential treatment for cervical dysplasia • Trial successfully
Slide 32: Completed Phase 2 Trial in HIV-Negative Participants
VGX-3100 ANAL HSIL Completed Phase 2 Trial in HIV-Negative Participants Precancerous 3 or 4 dose regimen Phase 2 Anal Dysplasia: open-label trial N=24 at Months 0, 1, 3 and Week 36 (optional) Final findings Clearance of HPV-16/18+ lesions: The Spontaneous Rate (6 months after start of treatment) 50%
Slide 33: Ongoing Phase 2 Trial in HIV-Positive Participants
VGX-3100 ANAL HSIL Ongoing Phase 2 Trial in HIV-Positive Participants • Trial initiated in September 2018 - 80-participant, open-label Phase 2 trial - Final 4 doses at week 0, 4, 12, and 24 findings (6 months after start of treatment) • Primary endpoint: overall response rate at 48 weeks – defined a
Slide 34: Next-Generation DNA Medicine
Next-Generation DNA Medicine • Innovative technology builds on strengths of platform • Potential to transform treatment paradigm in rare disease
Slide 35: Next-Gen Technology Enables In Vivo Production of Monoclonal Antibodies
DMAbTM DNA ENCODED MONOCLONAL ANTIBODIES Next-Gen Technology Enables In Vivo Production of Monoclonal Antibodies MYOCYTE • DNA is administered via CELLECTRA device to enable local expression of the genes coding for the antibodies in the deltoid muscle. • DMAbs are expressed and assembled in myocytes
Slide 36: DMAb Ongoing Phase 1 Trial: Data Published in Nature Medicine
DMAbTM Ongoing Phase 1 Trial: Data Published in Nature Medicine • Long-lasting in vivo antibody production: DURABLE AND CONSISTENT DMAb EXPRESSION DMAb levels remained stable for 96 weeks in all participants reaching that timepoint 2048 Serum Concentration, ng/mL • No anti-drug antibodies (ADA): no
Slide 37: Potential to Address Challenges of Conventional mAbs
DMAbTM Potential to Address Challenges of Conventional mAbs Challenges with mAbs1 INOVIO’s DMAb technology • Stability: susceptible to a variety of chemically- • Rapid manufacturing, low cost of production, and and temperature-induced structural changes temperature-stable storage and distribution •
Slide 38: Potential Shown in Multiple Disease Models
DMAbTM Potential Shown in Multiple Disease Models • Delivery of anti PCSK-9 in mice lowers LDL PCSK-9 Influenza A & B • Broadly neutralizing pan-influenza A & B approach cholesterol (Khoshnejad et al Mol Ther 2018) • Delivery of multiple antibodies (Elliott et al NJV 2017) viruses • Demonstrated dis
Slide 39: Potential as a New Treatment Paradigm in Rare Diseases
DPROT DNA-ENCODED PROTEINS Potential as a New Treatment Paradigm in Rare Diseases • Builds on DMAb technology FACTOR VIII PROTEIN STRUCTURE - Targets long-term protein expression, with ability to re-dose due to lack of anti-vector immunity • Aims to address shortcomings of conventional therapeutic p
Slide 40: INOVIO Partnerships
INOVIO Partnerships PRODUCT INDICATION PHASE SPONSOR FUNDERS/COLLABORATORS VGX-3100 Cervical Dysplasia (HSIL) – China 3 VGX-3100 Anal Dysplasia (HSIL) – HIV+ 1 INO-5401 Glioblastoma 1/2 INO-5412 Glioblastoma 2 INO-5401 BRCA 1/2 Mutation 1 INO-4800 COVID-19 (Solidarity) 3 INO-6172 HIV 1 INO-6160 HIV
Slide 41: Progressing Strategy to Unlock the Promise of DNA Medicine
Progressing Strategy to Unlock the Promise of DNA Medicine NEAR TERM MID TERM NEXT GEN Working to Deliver Advancing Diversified Innovating NextGen INO-3107 to Patients Clinical Pipeline DNA Medicines • BLA accepted for review under • Additional clinical candidate • DMAbs: accelerated approval progra
Slide 42: Thank you
Thank you Investors: Peter Vozzo Peter.Vozzo@icrhealthcare.com Media: Jennie Willson Jennie.Willson@inovio.com
INOVIO Pharmaceuticals — Investor Presentation (June 2026) on 6ix